Shares of Eli Lilly (LLY) are down 4.7% compared with a year ago. The company reports third-quarter fiscal 2016 results on Oct. 25, and investors are waiting for a catalyst.
Eli Lilly lost patent protection on the antidepressant Cymbalta in 2013, and the loss wrecked the company’s top line. At its peak, Cymbalta had revenue of $5.1 billion. This year, analysts are forecasting Cymbalta revenue of just $700 million.
